Versantis

company

About

Versantis is a pharmaceutical company developing medicine to revolutionize the care of patients.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
Fr16M
Industries
Health Care,Health Diagnostics,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

Versantis is a Swiss pharmaceutical company developing medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide.

Its lead candidate, VS-01, is currently at the preclinical stage and has the potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 targets 3 rare indications and received an Orphan Drug Designation in ALF. In addition, Versantis’ pipeline promises to improve patients’ outcomes in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities and significant upsides for Versantis.

Versantis was established in 2015 by Meriam Kabbaj in Zurich, Switzerland.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Fr16M
Versantis has raised a total of Fr16M in funding over 2 rounds. Their latest funding was raised on Sep 18, 2019 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 18, 2019 Series B Fr16M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Versantis is funded by 1 investors. Verve Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Verve Ventures Series B